Phenylethylamine (PEA) Overview

1) Studied Conditions

Phenylethylamine has been studied for its potential effects on a variety of conditions such as:

• Depression
• Attention deficit hyperactivity disorder (ADHD)
• Weight loss
• Physical performance enhancement
• Cognitive enhancement

2) Effectiveness in Treating Conditions

Research on phenylethylamine for these conditions has shown mixed results:

• In some cases, it may exhibit mood-enhancing properties, but the evidence is not strong enough to conclusively support its use for treating depression or other mood disorders.
• Its role in ADHD and cognitive enhancement is not well-established and requires more research.
• There is limited evidence to suggest it may aid in weight loss and improve physical performance, but these effects are not well-substantiated.

3) Health Benefits

Health benefits of phenylethylamine may include:

• Mild mood improvement due to its role as a neuromodulator.
• Potential increase in energy levels and focus.
• Some users report enhanced well-being and alertness.

4) Downsides

While phenylethylamine is naturally occurring in the body and certain foods, it may have downsides:

• Can cause side effects such as headaches, nausea, and dizziness.
• May lead to rapid heart rate or increased blood pressure in some individuals.
• There is potential for abuse and dependency with excessive use.
• Due to its stimulant effects, it may not be suitable for individuals with certain cardiovascular conditions.

5) Genetic Variations

Phenylethylamine's effects might vary depending on individual genetic variations:

• Individuals with specific polymorphisms in the monoamine oxidase B (MAO-B) gene may metabolize phenylethylamine differently, affecting its impact on mood and cognition.
• Genetic variations can influence the sensitivity to the stimulant effects of phenylethylamine, potentially leading to a greater risk of side effects in some people.
• More research is needed to fully understand the relationship between genetic variations and the effects of phenylethylamine.

Phenylethylamine (PEA) and Food Processing

The Prüß research team discovered that β-phenylethylamine (PEA) significantly reduces bacterial cell counts and biofilm amounts of Escherichia coli O157:H7 in liquid beef broth medium. PEA's properties as a trace amine neurotransmitter show that it functions differently than biogenic amines like serotonin or dopamine. Low levels of PEA are linked to attention deficit hyperactivity disorder (ADHD), suggesting it as a safer alternative to stimulant drugs with side effects. PEA can indicate bacterial contamination in food processing, as it appears in microbial metabolism or thermal processing.

Phenylethylamine (PEA) in Algae and Natto Products

Alkaloids found in marine algae, including phenylethylamine alkaloids, have pharmacological properties and are of interest for drug development. A study on Korean Natto products revealed that some contained β-phenylethylamine or tyramine levels above the toxic threshold, indicating a health risk. Bacillus subtilis strains isolated from these products were proficient in producing these amines.

Phenylethylamine (PEA) in Commercial Eggs

An assessment of commercial eggs showed that egg quality, especially from older hens, declined over time. Chromatographic analysis found the presence of phenylethylamine in all egg whites at a concentration of 38.0 mg/kg. The age of the hens and storage conditions significantly affected egg quality parameters, although bioactive amines could not be used to establish a quality index for the eggs.

Phenylethylamine (PEA) in Cocoa

A new method applied to cocoa samples found that amine concentrations increased during fermentation and roasting, with 2-phenylethylamine levels much higher than its corresponding aldehyde, phenylacetaldehyde. This indicates a heat-driven formation pathway for "biogenic amines" in roasted cocoa.

Phenylethylamine (PEA) and its Role in the Brain

PEA, transformed from phenylalanine by decarboxylation, has a short lifespan in the brain due to degradation by MAO-B. It acts similarly to an endogenous amphetamine and is associated with various psychological disorders. Monitoring PEA levels could be valuable for treating individual psychotic patients.

Phenylethylamine (PEA) and Phenylketonuria (PKU)

Phenylalanine hydroxylase (PAH) metabolizes dietary phenylalanine, and mutations in the PAH gene can cause PKU. The traditional treatment involves a phenylalanine-restricted diet, and genotype analysis can aid in treatment. Advances in understanding PAH's structure and function have implications for its evolutionary development and disease treatment.

Phenylethylamine (PEA) as a Neurotransmitter Modulator

PEA is suggested to modulate catecholamine transmission within the mammalian central nervous system. It may influence the release, reuptake, or breakdown of catecholamines, altering their signaling and effects in the brain. This could contribute to the development of new treatments for neurological or psychiatric disorders.

References:

1. β-phenylethylamine, a small molecule with a large impact
2. Following the trace of elusive amines
3. Alkaloids in marine algae
4. Biogenic amine formation and bacterial contribution in Natto products
5. Bioactive amines and internal quality of commercial eggs
6. Formation of amines and aldehydes from parent amino acids during thermal processing of cocoa and model systems: new insights into pathways of the strecker reaction
7. Does phenylethylamine act as an endogenous amphetamine in some patients?
8. Phenylalanine hydroxylase: function, structure, and regulation
9. Phenylalanine hydroxylase deficiency
10. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?
11. Mutations in the phenylalanine hydroxylase gene: methods for their characterization
12. Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population
13. The isolation of N-methyl beta-phenylethylamine from Acacia berlandieri
14. The isolation and identification of three alkaloids from Acacia Berlandieri
15. Physiologic effects and plasma kinetics of beta-phenylethylamine and its N-methyl homolog in the dog
16. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors
17. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine
18. Trace amines: identification of a family of mammalian G protein-coupled receptors
19. Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1
20. Primate trace amine receptor 1 modulation by the dopamine transporter
21. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
22. Cloning, expression, and functional analysis of rhesus monkey trace amine-associated receptor 6: evidence for lack of monoaminergic association
23. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor
24. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity
25. Biogenic amines activate blood leukocytes via trace amine-associated receptors TAAR1 and TAAR2
26. Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists
27. Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception
28. Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain
29. Serotonin autoreceptor function and antidepressant drug action
30. Autoreceptor-mediated inhibition of norepinephrine release in rat medial prefrontal cortex is maintained after chronic desipramine treatment
31. Identification and distribution of beta-phenylethylamine in the rat
32. Enzymatic isotopic assay for and presence of beta-phenylethylamine in brain
33. Rat brain-uptake index for phenylethylamine and various monomethylated derivatives
34. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection
35. β-Phenylethylamine requires the dopamine transporter to increase extracellular dopamine in Caenorhabditis elegans dopaminergic neurons
36. Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain
37. Oxidation of beta-phenylethylamine by both types of monoamine oxidase: examination of enzymes in brain and liver mitochondria of eight species
38. Deamination of beta-phenylethylamine by monoamine oxidase--inhibition by imipramine
39. The potentiation of cortical neuron responses to noradrenaline by 2-phenylethylamine is independent of endogenous noradrenaline
40. Characterization of N-methylphenylethylamine and N-methylphenylethanolamine as substrates for type A and type B monoamine oxidase
41. Demonstration and distribution of phenylethanolamine in brain and other tissues
42. Location, development, control, and function of extraadrenal phenylethanolamine N-methyltransferase
43. Kinetic and pH studies on human phenylethanolamine N-methyltransferase
44. Oxidation of phenylethanolamine and octopamine by type A and type B monoamine oxidase. Effect of substrate concentration
45. Phenylethanolamine is a specific substrate for type B monoamine oxidase
46. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons
47. Effects of synephrine and beta-phenethylamine on human alpha-adrenoceptor subtypes
48. Action of beta-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission
49. Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine
50. In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine
51. Effects of beta-phenylethylamine on dopaminergic neurons of the ventral tegmental area in the rat: a combined electrophysiological and microdialysis study
52. Evidence for carrier-mediated efflux of dopamine from corpus striatum
53. Effects of phenethylamine derivatives on the release of biogenic amines from synaptosomes
54. beta-Phenylethylamine regulation of dopaminergic nigrostriatal cell activity
55. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice
56. Characterization of beta-phenylethylamine-induced monoamine release in rat nucleus accumbens: a microdialysis study
57. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys
58. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial
59. Opponent interactions between serotonin and dopamine
60. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs
61. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions
62. Dopamine/serotonin releasers as medications for stimulant addictions
63. Acute aerobic exercise and affect: current status, problems and prospects regarding dose-response
64. Phenylethylamine, a possible link to the antidepressant effects of exercise?
65. Expression of neuronal trace amine-associated receptor (Taar) mRNAs in leukocytes
66. HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes
67. ß-Phenylethylamine as a novel nutrient treatment to reduce bacterial contamination due to Escherichia coli O157:H7 on beef meat
68. Octopamine and phenylethylamine inhibit prolactin secretion both in vivo and in vitro
69. Prolactin inhibition by p-tyramine in the male rat: site of action
70. Dopamine as a prolactin (PRL) inhibitor
71. Striatal shape in Parkinson's disease
72. The biosynthesis of p-tyramine, m-tyramine, and beta-phenylethylamine by rat striatal slices
73. Electrical stimulation of the substantia nigra and changes of 2-phenylethylamine synthesis in the rat striatum
74. Decreased beta-phenylethylamine in CSF in Parkinson's disease
75. Plasma beta-phenylethylamine in Parkinson's disease
76. Effect of sympathomimetic drugs in eliciting hypertensive responses to reserpine in the rat, after pretreatment with monoamineoxidase inhibitors
77. Selective inhibitors of monoamine oxidase type B and the "cheese effect"
78. MAO inhibitors: risks, benefits, and lore
79. Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation
80. Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy
81. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism
82. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function
83. Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!